Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SuppreMol Begins Development of SM401 to Diagnose and Treat RA

Published: Wednesday, July 25, 2012
Last Updated: Tuesday, July 24, 2012
Bookmark and Share
Licensing agreement with the University Hospital of Regensburg.

SuppreMol GmbH has announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA).

SuppreMol will advance preclinical development of SM401 for treatment of RA.

Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

SuppreMol’s preclinical candidate SM401 has demonstrated, in a murine model for RA, that it significantly reduces progression and severity of the disease.

At the same time, levels of the inflammatory cytokines IL-6 and TNF-alpha, which are reduced by several established RA drugs, are also lowered.

Furthermore, it has been demonstrated that IL-3 concentrations were only elevated at the onset of arthritis and fell to low levels during the course of the disease in the animal model.

Using the newly developed IL-3 diagnostic assay, SuppreMol expects to develop a biomarker for the stratification of RA patients.

“This SM401 program advances SuppreMol's strategy to target very early events in the development of autoimmune diseases,” said Dr. Peter Sondermann, CSO and co-founder of SuppreMol GmbH.

Dr. Sondermann continued, “Through this early intervention approach we expect to stop progression of the autoimmune disease rather than simply treating symptoms of inflammation. We expect to begin clinical trials in 2014.”

The anti-IL-3 monoclonal antibody was generated by the group of Professor Dr. Matthias Mack at Regensburg University Hospital - Internal Medicine II, following the discovery that increased levels of IL-3 indicate early onset and activity of RA. Prof. Mack is a member of SuppreMol’s Scientific Advisory Board.

“This licensing agreement with Bayerische Patentallianz GmbH provides SuppreMol a very strong portfolio of autoimmune therapies and a potential companion RA diagnostic,” said Professor Dr. Peter Buckel, CEO of SuppreMol GmbH.

“Along with our Fc gamma receptor platform with three clinical and two further preclinical programs targeting autoimmune diseases and allergies, this SM401 program is another building block in the strong foundation of the company’s future,” he added.

Bayerische Patentallianz GmbH is the central patent and marketing agency of the Bavarian Universities and Universities of Applied Sciences, including the University of Regensburg.

Early development of SM401 is being funded by a grant of € 1.37 million from the German Federal Ministry of Education and Research (BMBF).

The project was funded in Prof. Mack’s laboratory through BayImmuNet, the Bayerisches Immuntherapie Netzwerk; the development of a therapeutic anti-IL-3 antibody including a highly sensitive IL-3 assay is supported by the German Federal Ministry of Education and Research within the Leading-Egde Cluster “m4 - Personalized Medicine and Targeted Therapies” in Munich.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!